Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX) will participate in the RBC Capital Markets Global Healthcare Conference on May 19, 2026. Pliant’s CEO Bernard Coulie, M.D., Ph.D., and CFO Keith Cummings, M.D., will take part in a fireside chat at 11:30 a.m. ET. A live webcast will be available via the company’s Investor Relations Events & Presentation page, and a replay will be archived for 30 days following the event.

News Market Reaction – PLRX

+1.65%

+1.65% Session close to close

In the May 6 session, PLRX gained 1.65%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Pliant’s investor-relations activity, with leadership presenting at the...

Analysis

This announcement highlights Pliant’s investor-relations activity, with leadership presenting at the RBC Capital Markets Global Healthcare Conference on May 19, 2026. It complements recent clinical and corporate updates around PLN-101095 and option repricing actions. Investors may watch for any new disclosures during the fireside chat, while also monitoring the company’s effective $300,000,000 shelf registration and $50,000,000 ATM facility as potential capital-raising tools alongside its reported $192.4M cash balance and runway into H2 2028.

Key Figures

Shelf registration size: $300,000,000 ATM program size: $50,000,000 Shares outstanding: 61,914,664 shares +5 more

8 metrics

Shelf registration size $300,000,000 S-3 shelf filed March 30, 2026 for multiple security types

ATM program size $50,000,000 At-the-market offering capacity with Leerink Partners LLC

Shares outstanding 61,914,664 shares Common shares outstanding as of April 15, 2026 (DEF 14A)

Option exercise price $1.33 per share Company-wide option repricing effective April 17, 2026

Cash balance $192.4M Reported cash supporting operations into H2 2028 (Q4 2025 update)

Responders 4 of 10 patients Secondary ICI-refractory patients responding in highest-dose PLN-101095 cohorts

Median time on treatment 15 months Responders in PLN-101095 Phase 1 dose-escalation trial as of Nov 30, 2025

Disease control rate 60% Secondary ICI-refractory patients with stable disease or tumor reduction

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Trial expansion start	Positive	+0.8%	First patient dosed in FORTIFY Phase 1b indication expansion for PLN-101095.
Mar 18	Conference presentation	Positive	-3.8%	Upcoming Phase 1 PLN-101095 data presentation at AACR annual meeting.
Mar 11	Earnings & pipeline	Positive	+6.0%	Q4 2025 update with positive PLN-101095 data and cash runway into H2 2028.
Feb 23	Conference participation	Neutral	-0.8%	Planned fireside chat at Oppenheimer healthcare conference with webcast access.
Dec 04	Interim trial data	Positive	-14.9%	Interim PLN-101095 Phase 1 data in ICI-refractory tumors showing responses and durability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent conference and clinical updates have produced modest, mixed price reactions, with both positive and negative moves following generally constructive R&D news.

Recent Company History

Over the last six months, Pliant has focused updates on its oncology candidate PLN-101095 and corporate positioning. Interim Phase 1 data with durable responses and a Phase 1b expansion plan were followed by a 6.02% gain on Mar 11, 2026, while another interim update on Dec 4, 2025 saw a -14.94% move. Conference participation announcements on Feb 23, 2026 and the first-patient-dosed news on Apr 30, 2026 led to relatively small price changes, suggesting modest trading impact from similar informational updates.

Key Terms

clinical-stage biotechnology, integrin-based therapeutics

2 terms

clinical-stage biotechnology medical

"Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused"

Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.

integrin-based therapeutics medical

"company focused on the discovery and development of integrin-based therapeutics, today"

Integrin-based therapeutics are drugs or biologic treatments that target integrins, which are proteins on cell surfaces that act like Velcro and signaling switches to help cells stick to each other and respond to their environment. By blocking or activating these proteins, such therapies can change inflammation, tissue repair, cancer spread or clotting, so investors watch them as potential high-impact treatments that can create new markets, move clinical-stage valuations, and carry clinical and regulatory risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Keith Cummings, M.D., Pliant’s Chief Financial Officer, will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time.

Interested parties may access the live webcast of the RBC fireside chat by visiting the Investor Relations’ Events & Presentation page of Pliant’s website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant’s lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of α_vß₈ and α_vß₁ integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant’s preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells.

For additional information, please visit: www.PliantRx.com. Follow Pliant on social media at X, LinkedIn and Facebook.

Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When is Pliant Therapeutics (PLRX) speaking at the RBC Global Healthcare Conference in 2026?

Pliant will speak on May 19, 2026 at 11:30 a.m. ET. According to the company, CEO Bernard Coulie and CFO Keith Cummings will appear in a fireside chat at that time.

How can investors watch the Pliant Therapeutics (PLRX) RBC fireside chat live?

Investors can watch via the company’s Investor Relations Events & Presentation page. According to the company, a live webcast link will be provided on that page for the May 19, 2026 event.

Will Pliant Therapeutics (PLRX) provide a replay of the RBC conference presentation?

Yes, a replay will be available for 30 days after the event. According to the company, the webcast replay will be archived on Pliant’s website for one month following conclusion.

Who from Pliant Therapeutics (PLRX) will participate in the May 19, 2026 fireside chat?

Bernard Coulie, M.D., Ph.D., CEO, and Keith Cummings, M.D., CFO, will participate. According to the company, both executives will appear together in the fireside chat.

What topics will Pliant Therapeutics (PLRX) cover at the RBC Global Healthcare Conference?

The company announced executive participation but did not list specific topics. According to the company, the session is a fireside chat featuring CEO and CFO remarks and investor Q&A may follow.